New Drugs and Therapies at the Forefront of Treatment for Acute Lymphoblastic Leukemia

New Drugs and Therapies at the Forefront of Treatment for Acute Lymphoblastic Leukemia

New Drugs and Therapies at the Forefront of Treatment for Acute Lymphoblastic LeukemiaLocal firm supplies active pharmaceutical ingredients to various global pharmaceutical companies who develop new therapies.

BOCA RATON, Florida – Promising news for families with children suffering from acute lymphoblastic leukemia, or ALL, was recently published in Reuters Health. Results were released from a study conducted at the University of Colorado School of Medicine and Children’s Hospital, which revealed significant gains in the fight against childhood leukemia have been made.

Data gleaned from this study showed that of 20,000 babies, children and adolescents who had ALL, the survival rate of at least five years after the initial diagnosis increased, from 84 percent in the early 1990’s to 90 percent a decade later. This research is hopeful, especially considering the fact that 98 percent of childhood leukemias are classified as acute lymphocytic leukemia. In addition, 25 percent of all childhood cancers are leukemia, which amount to roughly 2,200 American children each year.

According to Mendy Schurder, COO of LGM Pharma, a leading supplier of active pharmaceutical ingredients (APIs) to global pharmaceutical firms, “LGM Pharma supplies APIs to University and research companies who develop new therapies and drugs to help combat this disease. The exploration of personalized medical care through the use of Theranostics—diagnostics that are closely tied to a specific drug treatment—is poised to become the next wave of pharmaceutical revelations and customized care.”

Researchers also received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. Of the 65 patients in the single-arm study, 20 percent experienced a complete or nearly complete response, with a median duration of 5.4 months, and an overall 7.7 month survival rate. This news is the latest in several galvanizing reports released regarding new and innovative treatments for acute lymphoblastic leukemia.

“As a cancer of the bone marrow and blood, the child with leukemia has bone marrow that begins to make blood cells that don’t mature properly,” explains Robert Hoppes, Director of Sales “These immature cells continue to reproduce, thus crowding out the healthy cells. Effective treatment is not only crucial, it is also completely within reach for scientists today. Only fifty years ago childhood leukemia was considered an incurable disease, and literally all children affected by it did not survive.”

About LGM Pharma

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service